Picture of Biohaven Pharmaceutical Holding logo

BHVN — Biohaven Pharmaceutical Holding Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapMomentum Trap

Momentum

Relative Strength (%)
1m+10.74%
3m+43.63%
6m+49.46%
1yr+77%
Volume Change (%)
10d/3m-42.9%
Price vs... (%)
52w High-4.2%
50d MA+15.7%
200d MA+14.64%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-65.64%
Return on Equityn/a
Operating Margin-70.8%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biohaven Pharmaceutical Holding EPS forecast chart

Profile Summary

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company. The Company has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The Company's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
September 25th, 2013
Public Since
May 4th, 2017
No. of Shareholders
70
No. of Employees
928
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNew York Stock Exchange
Shares in Issue
71,043,181

BHVN Share Price Performance

Upcoming Events for BHVN

Q2 2022 Biohaven Pharmaceutical Holding Company Ltd Earnings Release

Q3 2022 Biohaven Pharmaceutical Holding Company Ltd Earnings Release

Similar to BHVN

Picture of ADC Therapeutics SA logo

ADC Therapeutics SA

us flag iconNew York Stock Exchange

Picture of Ambrx Biopharma logo

Ambrx Biopharma

us flag iconNew York Stock Exchange

Picture of Annovis Bio logo

Annovis Bio

us flag iconNew York Stock Exchange

Picture of Arcus Biosciences logo

Arcus Biosciences

us flag iconNew York Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email